Literature DB >> 18408560

Association of corticotropin-releasing hormone receptor-2 genetic variants with acute bronchodilator response in asthma.

Audrey H Poon1, Kelan G Tantisira, Augusto A Litonjua, Ross Lazarus, Jingsong Xu, Jessica Lasky-Su, John J Lima, Charles G Irvin, John P Hanrahan, Christoph Lange, Scott T Weiss.   

Abstract

OBJECTIVE: Corticotropin-releasing hormone receptor (CRHR)-2 participates in smooth muscle relaxation response and may influence acute airway bronchodilator response to short-acting beta2-agonist treatment of asthma. We aim to assess associations between genetic variants of CRHR2 and acute bronchodilator response in asthma.
METHODS: We investigated 28 single nucleotide polymorphisms in CRHR2 for associations with acute bronchodilator response to albuterol in 607 Caucasian asthmatic patients recruited as part of the Childhood Asthma Management Program. Replication was conducted in two Caucasian adult asthma cohorts--a cohort of 427 participants enrolled in a completed clinical trial conducted by Sepracor Inc. (Massachusetts, USA) and a cohort of 152 participants enrolled in the Clinical Trial of Low-Dose Theophylline and Montelukast conducted by the American Lung Association Asthma Clinical Research Centers.
RESULTS: Five variants were significantly associated with acute bronchodilator response in at least one cohort (P<or=0.05). Variant rs7793837 was associated in Childhood Asthma Management Program and Low-Dose Theophylline and Montelukast (P=0.05 and 0.03, respectively) and haplotype blocks residing at the 5' end of CRHR2 were associated with response in all three cohorts.
CONCLUSION: We report for the first time, at the gene level, replicated associations between CRHR2 and acute bronchodilator response. Although no single variant was significantly associated in all three cohorts, the findings that variants at the 5' end of CRHR2 are associated in each of three cohorts strongly suggest that the causative variants reside in this region and its genetic effect, although present, is likely to be weak.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18408560      PMCID: PMC3208318          DOI: 10.1097/FPC.0b013e3282fa760a

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN: 1744-6872            Impact factor:   2.089


  34 in total

1.  Clinical trial of low-dose theophylline and montelukast in patients with poorly controlled asthma.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2006-09-22       Impact factor: 21.405

2.  Activation of corticotropin-releasing factor receptor-2 causes bronchorelaxation and inhibits pulmonary inflammation in mice.

Authors:  James D Moffatt; Rebecca Lever; Clive P Page
Journal:  FASEB J       Date:  2006-07-19       Impact factor: 5.191

3.  Beta2-ADR haplotypes/polymorphisms associate with bronchodilator response and total IgE in grass allergy.

Authors:  G Woszczek; M Borowiec; A Ptasinska; S Kosinski; R Pawliczak; M L Kowalski
Journal:  Allergy       Date:  2005-11       Impact factor: 13.146

4.  Enhanced expression of urocortin in lung tissues of rats with allergic asthma.

Authors:  Yuqing Wu; Hong Zhou; Yinyan Xu; Shengnan Li
Journal:  Biochem Biophys Res Commun       Date:  2006-01-13       Impact factor: 3.575

5.  Beta 2-adrenergic receptor polymorphisms: pharmacogenetic response to bronchodilator among African American asthmatics.

Authors:  Hui-Ju Tsai; Nishat Shaikh; Jennifer Y Kho; Natalie Battle; Mariam Naqvi; Daniel Navarro; Henry Matallana; Craig M Lilly; Celeste S Eng; Gunjan Kumar; Shannon Thyne; H George Watson; Kelley Meade; Michael LeNoir; Shweta Choudhry; Esteban G Burchard
Journal:  Hum Genet       Date:  2006-04-05       Impact factor: 4.132

Review 6.  Molecular mechanisms of beta(2)-adrenergic receptor function, response, and regulation.

Authors:  Malcolm Johnson
Journal:  J Allergy Clin Immunol       Date:  2006-01       Impact factor: 10.793

7.  Identifying 'well-controlled' and 'not well-controlled' asthma using the Asthma Control Questionnaire.

Authors:  Elizabeth F Juniper; Jean Bousquet; Linda Abetz; Eric D Bateman
Journal:  Respir Med       Date:  2005-10-13       Impact factor: 3.415

8.  Molecular properties and pharmacogenetics of a polymorphism of adenylyl cyclase type 9 in asthma: interaction between beta-agonist and corticosteroid pathways.

Authors:  Kelan G Tantisira; Kersten M Small; Augusto A Litonjua; Scott T Weiss; Stephen B Liggett
Journal:  Hum Mol Genet       Date:  2005-05-06       Impact factor: 6.150

Review 9.  The molecular mechanisms underlying the regulation of the biological activity of corticotropin-releasing hormone receptors: implications for physiology and pathophysiology.

Authors:  Edward W Hillhouse; Dimitris K Grammatopoulos
Journal:  Endocr Rev       Date:  2006-02-16       Impact factor: 19.871

10.  A graphical assessment of p-values from sliding window haplotype tests of association to identify asthma susceptibility loci on chromosome 11q.

Authors:  Rasika A Mathias; Peisong Gao; Janet L Goldstein; Alexander F Wilson; Elizabeth W Pugh; Paulette Furbert-Harris; Georgia M Dunston; Floyd J Malveaux; Alkis Togias; Kathleen C Barnes; Terri H Beaty; Shau-Ku Huang
Journal:  BMC Genet       Date:  2006-06-14       Impact factor: 2.797

View more
  18 in total

1.  A genome-wide association study of bronchodilator response in Latinos implicates rare variants.

Authors:  Katherine A Drake; Dara G Torgerson; Christopher R Gignoux; Joshua M Galanter; Lindsey A Roth; Scott Huntsman; Celeste Eng; Sam S Oh; Sook Wah Yee; Lawrence Lin; Carlos D Bustamante; Andrés Moreno-Estrada; Karla Sandoval; Adam Davis; Luisa N Borrell; Harold J Farber; Rajesh Kumar; Pedro C Avila; Emerita Brigino-Buenaventura; Rocio Chapela; Jean G Ford; Michael A Lenoir; Fred Lurmann; Kelley Meade; Denise Serebrisky; Shannon Thyne; William Rodríguez-Cintrón; Saunak Sen; José R Rodríguez-Santana; Ryan D Hernandez; Kathleen M Giacomini; Esteban G Burchard
Journal:  J Allergy Clin Immunol       Date:  2013-08-29       Impact factor: 10.793

Review 2.  The pharmacogenetics of asthma treatment.

Authors:  Kelan Tantisira; Scott Weiss
Journal:  Curr Allergy Asthma Rep       Date:  2009-01       Impact factor: 4.806

Review 3.  Genetic predictors of response to therapy in childhood asthma.

Authors:  Stephen W Turner
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

4.  Polymorphisms in recent GWA identified asthma genes CA10, SGK493, and CTNNA3 are associated with disease severity and treatment response in childhood asthma.

Authors:  Petra Perin; Uroš Potočnik
Journal:  Immunogenetics       Date:  2014-01-10       Impact factor: 2.846

Review 5.  Genetics of allergic diseases.

Authors:  Romina A Ortiz; Kathleen C Barnes
Journal:  Immunol Allergy Clin North Am       Date:  2014-11-21       Impact factor: 3.479

6.  Corticotropin-releasing hormone receptor-1 and 2 activity produces divergent resistance against stress-induced pulmonary Streptococcus pneumoniae infection.

Authors:  Byung-Jin Kim; Kay Kayembe; Jerry W Simecka; Mark Pulse; Harlan P Jones
Journal:  J Neuroimmunol       Date:  2011-07-20       Impact factor: 3.478

7.  Inhaled corticosteroid treatment modulates ZNF432 gene variant's effect on bronchodilator response in asthmatics.

Authors:  Ann Chen Wu; Blanca E Himes; Jessica Lasky-Su; Augusto Litonjua; Stephen P Peters; John Lima; Michiaki Kubo; Mayumi Tamari; Yusuke Nakamura; Weiliang Qiu; Scott T Weiss; Kelan Tantisira
Journal:  J Allergy Clin Immunol       Date:  2013-11-23       Impact factor: 10.793

8.  Predicting response to short-acting bronchodilator medication using Bayesian networks.

Authors:  Blanca E Himes; Ann Chen Wu; Qing Ling Duan; Barbara Klanderman; Augusto A Litonjua; Kelan Tantisira; Marco F Ramoni; Scott T Weiss
Journal:  Pharmacogenomics       Date:  2009-09       Impact factor: 2.533

Review 9.  Pharmacogenetics and the development of personalized approaches for combination therapy in asthma.

Authors:  Stacey M Miller; Victor E Ortega
Journal:  Curr Allergy Asthma Rep       Date:  2013-10       Impact factor: 4.806

10.  Genome-wide association study of short-acting β2-agonists. A novel genome-wide significant locus on chromosome 2 near ASB3.

Authors:  Elliot Israel; Jessica Lasky-Su; Amy Markezich; Amy Damask; Stanley J Szefler; Brooke Schuemann; Barbara Klanderman; Jody Sylvia; Shamsah Kazani; Rongling Wu; Fernando Martinez; Homer A Boushey; Vernon M Chinchilli; Dave Mauger; Scott T Weiss; Kelan G Tantisira
Journal:  Am J Respir Crit Care Med       Date:  2015-03-01       Impact factor: 30.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.